MX391145B - Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc). - Google Patents

Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc).

Info

Publication number
MX391145B
MX391145B MX2019005090A MX2019005090A MX391145B MX 391145 B MX391145 B MX 391145B MX 2019005090 A MX2019005090 A MX 2019005090A MX 2019005090 A MX2019005090 A MX 2019005090A MX 391145 B MX391145 B MX 391145B
Authority
MX
Mexico
Prior art keywords
sup
modulators
pyrdazine
rorc
derivatives
Prior art date
Application number
MX2019005090A
Other languages
English (en)
Other versions
MX2019005090A (es
Inventor
Alberto Gobbi
Andrew Cridland
Benjamin Fauber
Christopher Hurley
Emanuela Gancia
James J Crawford
Jason Zbieg
Jonathan Killen
Niel Monique Bodil Van
Olivier Rene
Patrick Cyr
Paul Winship
Sarah M Bronner
Stuart Ward
Wendy Lee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019005090A publication Critical patent/MX2019005090A/es
Publication of MX391145B publication Critical patent/MX391145B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I: (ver Fórmula) o sales de los mismos farmacéuticas, en donde m, n, p, q A, B, R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente. También se describen métodos para elaborar los compuestos y usar los compuestos para el tratamiento enfermedades inflamatorias tales como artritis.
MX2019005090A 2016-11-01 2017-10-31 Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc). MX391145B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415905P 2016-11-01 2016-11-01
PCT/EP2017/077931 WO2018083105A1 (en) 2016-11-01 2017-10-31 Pyridazine derivatives as rorc modulators

Publications (2)

Publication Number Publication Date
MX2019005090A MX2019005090A (es) 2019-09-02
MX391145B true MX391145B (es) 2025-03-21

Family

ID=60201586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005090A MX391145B (es) 2016-11-01 2017-10-31 Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc).

Country Status (10)

Country Link
US (1) US11008312B2 (es)
EP (1) EP3535255A1 (es)
JP (1) JP2019533000A (es)
KR (1) KR20190070985A (es)
CN (1) CN110225907A (es)
BR (1) BR112019008821A8 (es)
CA (1) CA3042317A1 (es)
MX (1) MX391145B (es)
RU (1) RU2757571C2 (es)
WO (1) WO2018083105A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883651A1 (en) * 2018-11-19 2021-09-29 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
JP4787321B2 (ja) * 2005-07-05 2011-10-05 エフ.ホフマン−ラ ロシュ アーゲー ピリダジン誘導体
WO2012014963A1 (ja) * 2010-07-29 2012-02-02 アステラス製薬株式会社 縮環ピリジン化合物
WO2015067575A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
MX2016008499A (es) * 2014-01-10 2016-09-13 Hoffmann La Roche Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).
WO2016177686A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag PYRIDAZINE DERIVATIVES AS RORc MODULATORS

Also Published As

Publication number Publication date
RU2019115791A (ru) 2020-12-03
CN110225907A (zh) 2019-09-10
MX2019005090A (es) 2019-09-02
RU2757571C2 (ru) 2021-10-18
KR20190070985A (ko) 2019-06-21
JP2019533000A (ja) 2019-11-14
US20190263794A1 (en) 2019-08-29
EP3535255A1 (en) 2019-09-11
BR112019008821A8 (pt) 2020-02-04
RU2019115791A3 (es) 2020-12-17
CA3042317A1 (en) 2018-05-11
WO2018083105A1 (en) 2018-05-11
US11008312B2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
EA201691491A1 (ru) Арильные и гетероарильные эфиры в качестве модуляторов ror-гамма
MX380239B (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona.
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MX394388B (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
CY1120340T1 (el) Gpr40 ρυθμιστες πυρρολιδινης για τη θεραπεια ασθενειων οπως διαβητη
UY34062A (es) ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?.
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
CY1118365T1 (el) Διαμορφωτες διυδροπυραζολης του gpr40
PE20151144A1 (es) Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias
MX386111B (es) Compuestos nuevos como moduladores de ror gamma.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
EA201691002A1 (ru) Бициклические гетероарильные аналоги индола, подходящие в качестве модуляторов ror гамма
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
MX2017001624A (es) Sal de derivado de piridina monociclico y su cristal.
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
BR112018070363A2 (pt) derivados de tetraidroisoquinolina